Avelumab + Paclitaxel/ Ramucirumab as Second Line Treatment in Gastro-esophageal Adenocarcinoma

Case Medical Research ◽

10.31525/ct1-nct03966118 ◽

2019 ◽

Author(s):

Keyword(s):

Esophageal Adenocarcinoma ◽

Line Treatment ◽

Download Full-text

Response to entecavir treatment and evolution of HBV quasispecies in patients with failure to second line treatment with adefovir

Zeitschrift für Gastroenterologie ◽

10.1055/s-0032-1332138 ◽

2013 ◽

Vol 51 (01) ◽

Author(s):

A Herber ◽

K Deterding ◽

C Jochum ◽

B Kronenberger ◽

HH Feucht ◽

...

Keyword(s):

Line Treatment ◽

Download Full-text

Survival by pattern of tumor progression during prior sorafenib (SOR) treatment in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial comparing second-line treatment with regorafenib (REG) or placebo

10.1055/s-0037-1605011 ◽

2017 ◽

Author(s):

P Galle ◽

P Merle ◽

A Granito ◽

YH Huang ◽

G Bodoky ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Tumor Progression ◽

Phase Iii ◽

Line Treatment ◽

Download Full-text

Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature

Journal of Neurosurgical Sciences ◽

10.23736/s0390-5616.16.03874-1 ◽

2019 ◽

Vol 63 (4) ◽

Author(s):

Salvatore Grisanti ◽

Vittorio D. Ferrari ◽

Michela Buglione ◽

Giorgio M. Agazzi ◽

Roberto Liserre ◽

...

Keyword(s):

Systematic Review ◽

Phase Ii ◽

Phase Ii Study ◽

Recurrent Glioblastoma ◽

Line Treatment ◽

Second Line ◽

Review Of Literature

Download Full-text

Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

Case Medical Research ◽

10.31525/ct1-nct03959293 ◽

2019 ◽

Author(s):

Keyword(s):

Clinical Trial ◽

Line Treatment ◽

Download Full-text

Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors

Case Medical Research ◽

10.31525/ct1-nct04010071 ◽

2019 ◽

Author(s):

Keyword(s):

Malignant Tumors ◽

Line Treatment ◽

Download Full-text

Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M

Case Medical Research ◽

10.31525/ct1-nct04029350 ◽

2019 ◽

Author(s):

Keyword(s):

Line Treatment ◽

Download Full-text

Faculty Opinions recommendation of Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718047126.793482089 ◽

2013 ◽

Author(s):

Thomas Stinchcombe

Keyword(s):

Lung Cancer ◽

Randomised Controlled Trial ◽

Small Cell Lung Cancer ◽

Controlled Trial ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Small Cell Lung ◽

Randomised Controlled

Download Full-text

Faculty Opinions recommendation of Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718451079.793497341 ◽

2014 ◽

Author(s):

Laurie Carr

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Disease Progression ◽

Stage Iv ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Phase 3 ◽

Download Full-text

Faculty Opinions recommendation of Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725347054.793541339 ◽

2018 ◽

Author(s):

Ravindra Sarode

Keyword(s):

Immune Thrombocytopenia ◽

Controlled Trial ◽

Line Treatment ◽

Second Line ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725347054.793527308 ◽

2017 ◽

Author(s):

Aimee Payne

Keyword(s):

Immune Thrombocytopenia ◽

Controlled Trial ◽

Line Treatment ◽

Second Line ◽

Double Blind ◽

Double Blind Placebo

Download Full-text